TwoOncDocs

🩸 a podcast about heme/onc for health care providers | ☕️ short high yield episodes to supplement your board review resources | @SamArmstrongMD @DrKarineTawagi

[Antonio Ocejo @ja_ocejo]

📣 Oncology fellows: Applications are open for the 2026–2027 FDA/ASCO Fellows’ Day Workshop!

Great way to learn from FDA oncology leaders about trial design, regulatory science, and the drug/device approval process through case-based discussions and Q&A.

📌Open to oncology fellows with at least one year of completed training.
🗓️ In-person + virtual options available, with up to $500 reimbursement for selected in-person participants.

Apply by June 26: https://t.co/5zHLj5aeoH
@ASCOTECAG @HemOncFellows @IMG_Oncologists

[TwoOncDocs @TwoOncDocs]

@KalantriShreyas @IMG_Oncologists @ASCO @AACR @ConquerCancerFd @JCO_ASCO @HemOncFellows @oncodaily @OncLive Congrats!!

[Ria Kraft, MD @riakraftmd]

It’s #radonc away rotation season! For #medstudents and junior #residents, here are my go-to resources in radiation oncology (1/2).

[TwoOncDocs @TwoOncDocs]

* #PROTEUS #SARC041

[TwoOncDocs @TwoOncDocs]

That’s a wrap for #ASCO26 💕

We are excited to dive in to our key takeaways in next week’s episode including some of the plenary sessions (#RASolute ‼️#SARC1, #PROTREUS) & more

📅 & save the date for our #ASH26 free heme board review session for trainees Dec 11🩸 @OncBrothers

[Allison Fitzgerald, MD, PhD @allisonoconn]

With all the excitement around daraxonrasib, I needed to refresh my RAS inhibitor knowledge, so here we go:

[Mark Lewis, MD, FASCO @marklewismd]

Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer

Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived

#ASCO26

[Yüksel Ürün @DrYukselUrun]

This is not simply a new pancreatic cancer drug.

It is a reminder that even “undruggable” biology can become treatable with persistence.

Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months.
A remarkable ASCO moment.
#ASCO26
@DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists

[TwoOncDocs @TwoOncDocs]

Standing ovation for a ***breakthrough*** in #pancreaticcancer 🥹🥹🥹

#RASolute today presented at #ASCO26:

Daraxonrasib DOUBLES the median overall survival in metastatic pancreatic cancer w/ +w/o RAS (mOS 13.2 mo vs. 6.6 mo)

A HUGE advance in one of the most lethal cancers 💜

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

A big moment for the sarcoma community at #ASCO26.

[TwoOncDocs @TwoOncDocs]

🤩SARCOMA AT PLENARY!🎗️
🔹 SARC041 provides the first randomized validation of CDK4 inhibition in DDLPS
📈 mPFS: 9.7 vs 1.5 mo (HR 0.39, p<0.001) — >6× improvement
🎯 ORR: 9.3% vs 0%
⏳ OS trend favors abemaciclib (HR 0.55)
🔄 Crossover activity confirmed (mPFS 3.4 mo)
#ASCO26

[TwoOncDocs @TwoOncDocs]

🚨 first up #PROTEUS Phase 3

Adding peri-op apalutamide to ADT significantly improves outcomes for high-risk localized prostate cancer undergoing surgery:

🔹 pCR/MRD: 8.9% vs 1.0% (10x OR!)

🔹 5-y MFS: 78.2% vs 73.5% (HR 0.80)

⚠️ 8% more gr3/4 tx AEs

#ProstateCancer #ASCO26

[TwoOncDocs @TwoOncDocs]

Full house for plenary! #ASCO26

🌟 LIBRETTO-432: adjuvant selpercatinib in stage IB-IIIA RET NSCLC

🌟 PROTEUS: apalutamide peri-op tx in PCa

🌟 RASolute 302: RAS inhibition in pancreatic cancer.

🌟 HARMONi-6: ivonescimab for NSCLC

🌟 SARC041: abemaciclib in liposarcoma

[Karine Tawagi MD @DrKarineTawagi]

Amazing work @GarradEvan presenting our work assessing AI use in heme/onc fellowship, simultaneously published @JCOOP_ASCO

▶️stay tuned on our HOF curriculum

https://t.co/QNwJmZaNM0

@TwoOncDocs @TheFellowOnCall @christinemphmd @DrJessDeLaune @DeepaRangachari @inas_md

#ASCO26

[Karine Tawagi MD @DrKarineTawagi]

PD breakfast #ASCO26 w/ our amazing LDP ESP crew🥰

& impt info on signals for the match🏅

✅for applicants: interviews jump from 9.5% to 25.5% w/ Silver and 52.3% w/ Gold

⚠️if you don't signal a program, the interview rate drops below 5%

▶️ tips on signals for programs

[Masood Pasha Syed MBBS MD FACP @MasoodPashaSyed]

At #ASCO2026 representing Ohio and advocating for a stronger future in cancer care.
The conversations we have here can shape the future of cancer care for years to come.
#ASCO #CancerCare #Oncology #Advocacy #Ohio #HealthPolicy

[TwoOncDocs @TwoOncDocs]

Our wonderful MSL & colleagues made their yearly list! For your exhibit wanderings 😋🍩 #ASCO26 @ASCO

[Kim Pulmano @kim_starr]

@LisaDamani are reporting back to you from #ASCO26 on booth treats! ‼️ This is not an exhaustive list. Comment on any we missed! We also want to hear what your personal favorites are! Enjoy! ☕️ 🍦 🍕 🌭 🍪

[Jon Trent, MD, PhD @JTrentMDPhD]

Great connecting with @SamArmstrongMD, leader of the @IndianaUniv #Sarcoma Team and mastermind of @TwoOncDocs #ASCO2026

[Mark Chang, DO @MarkChangDO]

My fav ASCO D2 highlight so far. Cheesing because we met half of @TwoOncDocs @ASCO @asco2026

[Ronak H. Mistry, DO @rmistry91]

PODCAST-HOF trial featuring @TheFellowOnCall and @TwoOncDocs and published in @JCO_ASCO-OP being highlighted as one of the biggest med ed research studies of the past year to know at the #ASCO26 Medical Education Committee on Practice event! 🎉